CGEN - Compugen Ltd Debt to Book Capitalization Ratio

Corporate company logo of cgen.com (CGEN)

Despite Middle East instability, Compugen Ltd. (CGEN) has moved its clinical trials to the US, where the indicator stands at 0.03. This price chart reflects the development of a business that minimizes environmental impact through digital modeling. Compugen Ltd. (CGEN) relies on highly qualified bioinformaticians, attracting industry elite with modern software and generous stock options to identify new oncological targets.

CGEN Compugen Ltd: Debt to Book Capitalization Ratio in the range 07/04/2022 - 10/27/2026
Finished products of Compugen Ltd

This ratio determines the company's degree of dependence on debt capital relative to its equity, reflecting the balance between financial stability and expansion rates. By analyzing the historical debt-to-book capitalization ratio, an investor sees the ratio of liabilities to asset value, which is critical for Compugen Ltd. (CGEN) when financing complex biomaterial logistics and establishing high-tech supply chains for immuno-oncology drugs.

Competitors of Compugen Ltd.

ImmunityBio, Inc. - Debts to Book Capitalization|immunocore.com - Debt to Book Value|JANX (Janux Therapeutics, Inc.) - Debt to Book Capitalization Ratio|RCUS: Debts to Book Value|Zymeworks Corp (ZYME) - Debt to Book Capitalization Ratio|TNGX (Tango Therapeutics Corp) - Debt to Book Capitalization Ratio|Debt to Book Capitalization Ratio IOVA (Iovance Biotherapeutics)|Debts to Book Value immatics.com|XNCR: Debts to Book Capitalization|Debt to Net Assets Compass Therapeutics Inc CMPX|REPL: Debt to Book Value|LYEL - Debts to Book Value|Debt to Book Value Innate Pharma S.A. (IPHA)|PYXS - Debt to Net Assets Ratio|IO Biotech - Debts to Book Capitalization|STRO (Sutro Biopharma Inc.) - Debts to Net Assets|Debt to Book Capitalization Ratio INKT|Debt to Book Value HOWL|Debt to Book Capitalization Ratio IMMX (Immix Biopharma, Inc.)|Debt to Book Value ALX Oncology Holdings Inc. ALXO|Debt to Book Value CUE (Cue Biopharma, Inc.)|PDS Biotech - Debts to Book Capitalization|Sonnet BioTherapeutics Holdings Inc. (SONN) - Debt to Book Capitalization Ratio|MAIA: Debt to Book Value Ratio|Debt to Book Capitalization Ratio LIMN|Debts to Book Value LAVA Therapeutics|NextCure - Debt to Book Value|Debt to Net Assets Leap Tx (LPTX)|Debt to Book Value Intensity Therapeutics|Debt to Book Capital senseibio.com (SNSE)|Debts to Book Capitalization Theriva Biologics, Inc.|Debt to Net Assets Ratio Gritstone bio Inc. GRTS|KA (Kineta) - Debts to Book Capitalization|NEXI: Debts to Book Value|Debt to Book Capitalization Ratio turnstonebio.com TSBX|Vaccinex Inc (VCNX) - Debt to Net Assets Ratio|HARP (Harpoon Therapeutics) - Debts to Book Capitalization